Youwen Tan

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Antiretroviral Therapy

Hepatitis C Virus

Prognostic Factors

Top Venues

Alimentary pharmacology & therapeutics

Open medicine (Warsaw, Poland)

Journal of viral hepatitis

This page only lists publications with an associated author ORCID identifier.

Publications

Youwen Tan, Xingbei Zhou
Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome. Medicine 103 (6) (2024)
Youwen Tan, Xingbei Zhou
Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome. Medicine 103 (6) (2024)
Youwen Tan, Sainan Zheng
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B can increase body weight. Alimentary pharmacology & therapeutics 59 (7) (2024)
Youwen Tan, Xingbei Zhou
Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome. Medicine 103 (6) (2024)
Youwen Tan, Sainan Zheng
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B can increase body weight. Alimentary pharmacology & therapeutics 59 (7) (2024)
Youwen Tan, Jiaming Wang
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics 57 (4) (2023)
Rui Hua, Fei Kong, Xiaofeng Wen, Qingfang Xiong, Jiayu Chen, Chenxin Meng, Hong Ma, Youwen Tan, Yan Huang, Yongfang Jiang, Yujuan Guan, Xiaorong Mao, Jiefei Wang, Yongning Xin, Hainv Gao, Bin Xu, Cheng Li, Qiong Wu, Xian Zhang, Zhiqiang Wang, Liwen Zhao, Yuexin Zhang, Guangming Li, Junqi Niu
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study. Journal of viral hepatitis 29 (6) (2022)
Youwen Tan, Yun Ye, Li Chen
Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review. Open medicine (Warsaw, Poland) 16 (1) (2021)